Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Free Cash Flow (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Free Cash Flow for 5 consecutive years, with -$11.0 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 23.35% to -$11.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$60.3 million through Dec 2025, down 6.82% year-over-year, with the annual reading at -$60.3 million for FY2025, 6.82% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$11.0 million at Werewolf Therapeutics, up from -$15.2 million in the prior quarter.
  • The five-year high for Free Cash Flow was -$632000.0 in Q2 2022, with the low at -$18.9 million in Q1 2025.
  • Average Free Cash Flow over 5 years is -$11.9 million, with a median of -$12.7 million recorded in 2022.
  • The sharpest move saw Free Cash Flow skyrocketed 94.02% in 2022, then tumbled 1617.56% in 2023.
  • Over 5 years, Free Cash Flow stood at -$13.1 million in 2021, then decreased by 15.91% to -$15.2 million in 2022, then surged by 66.02% to -$5.2 million in 2023, then tumbled by 178.94% to -$14.4 million in 2024, then rose by 23.35% to -$11.0 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$11.0 million, -$15.2 million, and -$15.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.